Yaron Almagor, M.D., director of the Interventional Cardiology and Cardiac Catheterization Laboratories at Shaare Zedek Medical Center in Jerusalem, Israel, performed the first implants.
“I am very pleased with the Tryton Stent System,” said Dr. Almagor. “Recently I had successful outcomes treating two patients with cases of complex true bifurcations – including one with left main disease, which can be very difficult to treat. I look forward to utilizing the Tryton stent to treat complex cases when it becomes commercially available for use in Israel.” Left main disease, an accumulation of plaque that narrows the base of the coronary tree, until recently has been treated with bypass surgery. Recent studies have demonstrated that stents may provide physicians and patients with an important alternative. Widespread adoption of stenting for left main disease has been hampered by the lack of a robust strategy for bifurcations lesions, which represent more than 75 percent of left main lesions. A Tryton strategy for left main disease has the potential to provide an important tool as stenting becomes established as a standard treatment for left main disease.
Professor Ran Kornowski, M.D., director of Interventional Cardiology at Rabin Medical Center and Tel Aviv University, who also participated in the first two cases and also performed a case in his hospital, added, “Based on our first successful experiences, the Tryton stent seems to be an important new tool for interventionists as we take on cases involving complex bifurcations and the distal segment of the left main coronary artery.”
“Bifurcation disease remains one of the last frontiers in treating coronary artery disease. The Tryton stent system – which has now been utilized to treat more than 1,300 patients – offers an innovative solution for these challenging cases. We are pleased that the Tryton solution will soon be available to clinicians and patients in Israel,” said J. Greg Davis, president and CEO of Tryton Medical.
The Tryton Stent System is currently in the process of obtaining regulatory approvals in Israel. The first three implants were performed under a special exemption approval by the Ministry of Health.
About the Tryton Side Branch Stent System
The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent system has received CE Mark approval in Europe and is commercially available in Austria, Belgium, Denmark, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. It is not approved in the United States.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company`s Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. The privately held company is backed by Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.
